Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.41 |
| ▸ | DPP4 | P27487 | 5/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 4/20 | 0.38 |
| ▸ | ARG1 | P05089 | 3/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL4296375 | 1.00 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL28079281 | 1.00 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL1696608 | 1.00 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL1537262 | 1.00 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL11660661 | 1.00 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL23834597 | 1.00 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL8520187 | 0.99 | GSR (0.56) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL21796038 | 0.96 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL22157986 | 0.96 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL1675387 | 0.96 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3326625-A1 | SYSTEMS, METHODS, AND FORMULATIONS FOR TREATING CANCER | Research Cancer Institute of America (US) | 2018-05-30 | — | — | EP | claimed |
| EP-2729008-B1 | SYSTEMS, METHODS, AND FORMULATIONS FOR TREATING CANCER | RES CANCER INST OF AMERICA (US) | 2017-04-05 | — | — | EP | claimed |
| US-20170007573-A1 | METHOD OF TREATING CANCER WITH COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS (HDAC1) SUBSTANCES | RESEARCH CANCER INSTITUTE OF AMERICA | 2017-01-12 | — | — | US | claimed |
| EP-2729008-A1 | SYSTEMS, METHODS, AND FORMULATIONS FOR TREATING CANCER | Research Cancer Institute of America (US) | 2014-05-14 | — | — | EP | claimed |
| WO-2013006821-A1 | SYSTEMS, METHODS, AND FORMULATIONS FOR TREATING CANCER | RESEARCH CANCER INSTITUTE OF AMERICA (US) | 2013-01-10 | — | — | WO | claimed |
| US-20130011488-A1 | Systems, Methods, and Formulations for Treating Cancer | RESEARCH CANCER INSTITUTE OF AMERICA | 2013-01-10 | — | — | US | claimed |
| EP-1796701-A1 | COMPOSITIONS FOR ANTI-OBESITY, HEALTH-RESTORATIVE AND HEALTH-PROMOTIONAL BENEFITS | Natreon Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| WO-2006036638-A1 | COMPOSITIONS FOR ANTI-OBESITY, HEALTH-RESTORATIVE AND HEALTH-PROMOTIONAL BENEFITS | NATREON, INC. (US) | 2006-04-06 | — | — | WO | claimed |
| US-20060062863-A1 | Compositions for anti-obesity, health-restorative and health-promotional benefits | NATREON INC. | 2006-03-23 | — | — | US | claimed |
| US-20050090480-A1 | Use of selected amino acid-zinc complexes as anti-malarials | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2005-04-28 | — | — | US | claimed |
| WO-2023133317-A1 | STABLE FORMULATIONS OF LIPID-ENCAPSULATED RNA | GREENLIGHT BIOSCIENCES, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| CN-116036076-A | Application of lithium amino acid in preparation of medicine for treating manic mental diseases | 安域生物科技(杭州)有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115813913-A | Application of proline or isobutyric acid in preparation of auxiliary drugs of central nervous excitation drugs | 安域生物科技(杭州)有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20160139140-A1 | MASS LABELS | ELECTROPHORETICS LIMITED (GB) | 2016-05-19 | — | — | US | disclosed |
| CN-105209921-A | Mass labels | ELECTROPHORETICS LTD | 2015-12-30 | — | — | CN | disclosed |
| WO-2002099435-A1 | METHOD FOR CHARACTERIZING POLYPEPTIDES | XZILLION GMBH & CO. KG (DE) | 2002-12-12 | — | — | WO | disclosed |
| US-5585233-A | MUTANT; GEBNETIC ENGINEERING | MAX-PLANCK GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1996-12-17 | — | — | US | disclosed |
| EP-0690918-A1 | PROTEIN TYROSINE PHOSPHATASE PTP-S31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994021800-A2 | PROTEIN TYROSINE PHOSPHATASE PTP-S31 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994012205-A1 | DYNORPHIN A SUPPRESSION OF NATURAL KILLER CELL ACTIVITY | THE ROCKEFELLER UNIVERSITY (US) | 1994-06-09 | — | — | WO | disclosed |